- PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000 from Chugai
- PharmaMar progresses in the clinical development of Zepsyre® in Japanwhile its ATLANTIS global registration trial in small-cell lung cancer continues
- ATLANTIS trial has successfully passed two safety analyses by the IDMC after inclusion of 150 and 500 patients, respectively . ...
SIGUIENTE ... : " IDEAYA BIOSCIENCES HA INICIADO UNA COLABORACIÓN CLÍNICA Con ASTRAZENECA " Para Probar el Conjugado Anticuerpo-Fármaco en Fase de Investigación IDE849 , Dirigido Contra la Proteína DLL3 TOP1 , Junto Con el Inhibidor de PD-L1 DURVALUMAB ( IMFINZI de ASTRAZENECA ) , en PACIENTES con SMALL CELL LUNG CANCER EXTENSIVE-STAGE .... ¿ PORQUE NO ELIGIERON AL ATEZOLIZUMAB ... ?
26 junio 2018
PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan .
MADRID, June 26, 2018 / PRNewswire/ .